1-sulfonyl-4-aminoalkoxy indole derivatives and uses thereof

Details 1-sulfonyl-4-aminoalkoxy indole derivatives and uses thereof 1-sulfonyl-4-aminoalkoxy indole derivatives and uses thereof

2003-06-04

2004-08-10

Aulakh, Charanjit S. (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C544S144000, C546S207000, C546S178000, C548S465000

Reexamination Certificate

active

06774241

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to 1-sulfonyl-4-aminoalkoxy indole derivatives, and associated compositions, methods for use as therapeutic agents, and methods of preparation thereof.
BACKGROUND OF THE INVENTION
The actions of the neurotransmitter 5-hydroxytryptamine (5-HT) as a major modulatory neurotransmitter in the brain, are mediated through a number of receptor families termed 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7. Based on a high level of 5-HT6 receptor mRNA in the brain, it has been stated that the 5-HT6 receptor may play a role in the pathology and treatment of central nerve system disorders. In particular, 5-HT6 selective ligands have been identified as potentially useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, migraine, Alzheimer's disease (enhancement of cognitive memory), sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Such compounds are also expected to be of use in the treatment of certain gastrointestinal (GI) disorders such as functional bowel disorder. See for example, B. L. Roth et al.,
J. Pharmacol. Exp. Ther.,
1994, 268, pages 1403-14120, D. R. Sibley et al.,
Mol. Pharmacol.,
1993, 43, 320-327, A. J. Sleight et al.,
Neurotransmission,
1995, 11, 1-5, and A. J. Sleight et al.,
Serotonin ID Research Alert,
1997, 2(3), 115-8. 5-HT6 antagonists have also been identified as potentially useful compounds for treatment of obesity. See for example, Bentley et al.,
Br. J. Pharmac.
1999, Suppl 126; Bently et al.,
J. Psychopharmacol.
1997, Suppl A64: 255; Wooley et al.,
Neuropharmacology
2001, 41: 210-129; and WO 02/098878.
While some 5-HT6 modulators have been disclosed, there continues to be a need for compounds that are useful for modulating 5-HT6.
SUMMARY OF THE INVENTION
The present invention provides a compound of the formula:
a pharmaceutically acceptable salt or a prodrug thereof,
wherein
n is 2 or 3;
each of R
1
and R
2
is independently hydrogen, lower alkyl, or R
1
and R
2
together with the nitrogen atom to which they are attached may form a heterocyclyl group;
each R
3
is independently hydrogen or alkyl, or R
3
and R
1
together with the nitrogen atom to which R
1
is attached may form a four to seven membered ring moiety with R
1
and R
3
together forming an alkylene group;
R
4
is hydrogen, lower alkyl, or haloalkyl;
R
5
is hydrogen, lower alkyl, halo, alkoxy, or haloalkyl; and
R
6
is optionally substituted aryl or optionally substituted heteroaryl.
The present invention also provides methods for preparing, compositions comprising, and methods for using Compounds of Formula I.


REFERENCES:
patent: 4582905 (1986-04-01), Sakai
patent: 5958965 (1999-09-01), Mewshaw et al.
patent: 6187805 (2001-02-01), Pineiro et al.
patent: 6509357 (2003-01-01), Zhou et al.
patent: 4134064 (1992-05-01), None
patent: WO 95/17398 (1995-06-01), None
patent: WO 97/25041 (1997-07-01), None
patent: WO 02/32863 (2002-04-01), None
patent: WO 02/36562 (2002-05-01), None
patent: WO 02/41889 (2002-05-01), None
patent: WO 02/059088 (2002-08-01), None
patent: WO 02/085853 (2002-10-01), None
patent: WO 02/085892 (2002-10-01), None
Sakai, Makiko, “Selective Cleavage of Unsymmetrical 2,2-spiro-1,3-dioxolanes. II. Cleavage of ketal ring of 5′-bromo-6′, 7′-dihydro-4-isopropylaminomethyl-1′-p-toluenesulfonylspiro[1,3-dioxolane-2,4′-(5′H)-indole] and its analogs,”Heterocycles,(1982), pp. 1269-1275, 19(7).
Fuji, Masahiro, et al., “Preparation of Alkyl-Substituted Indoles in the Benzene Portion. Part 7. Synthesis of (+ or −) and (S) —(−)-pindolol,”Chemical Pharm. Bulletin,(1992), pp. 2353-2357, 40(9).

Affiliated with

Also associated with

Rating

1-sulfonyl-4-aminoalkoxy indole derivatives and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1-sulfonyl-4-aminoalkoxy indole derivatives and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-sulfonyl-4-aminoalkoxy indole derivatives and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3309111